A living WHO guideline on drugs for COVID-19
BMJ
; 370: [1-14], Sept. 04, 2020.
Article
em En
| BIGG
| ID: biblio-1129878
Biblioteca responsável:
BR1.1
ABSTRACT
What is the role of drug interventions in the treatment of patients with covid-19? The latest version of this WHO living guidance focuses on remdesivir, following the 15 October 2020 preprint publication of results from the WHO SOLIDARITY trial. It contains a weak or conditional recommendation against the use of remdesivir in hospitalised patients with covid-19 The first version on this living guidance focused on corticosteroids. The strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic corticosteroids in patients with non-severe covid-19 are unchanged.
Texto completo:
1
Coleções:
05-specialized
Base de dados:
BIGG
Assunto principal:
Corticosteroides
/
Antirretrovirais
/
COVID-19
Tipo de estudo:
Guideline
Idioma:
En
Revista:
BMJ
Ano de publicação:
2020
Tipo de documento:
Article